Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Sep 3 2025 | Members and Leaders of HFSA to be Recognized at the 2025 Annual Scientific Meeting in Minneapolis, MN HFSA News Annual Scientific Meeting Read More Aug 30 2025 | Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial Industry News Industry Read More Aug 26 2025 | Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Industry News Industry Read More Aug 25 2025 | BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 Industry News Industry Read More Aug 14 2025 | HFSA Launches Nation’s First Comprehensive Heart Failure Clinic Database HFSA News Press Release Read More Pagination First page « First Previous page ‹ Previous … Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Page 12 Page 13 Page 14 … Next page Next › Last page Last »
Sep 3 2025 | Members and Leaders of HFSA to be Recognized at the 2025 Annual Scientific Meeting in Minneapolis, MN HFSA News Annual Scientific Meeting Read More
Aug 30 2025 | Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial Industry News Industry Read More
Aug 26 2025 | Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Industry News Industry Read More
Aug 25 2025 | BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 Industry News Industry Read More
Aug 14 2025 | HFSA Launches Nation’s First Comprehensive Heart Failure Clinic Database HFSA News Press Release Read More
